NEW YORK (GenomeWeb News) — WaferGen Biosystems and Qiagen KK, the Japanese subsidiary of Qiagen, said today that they have inked a co-marketing agreement for genomics products.

Under the agreement, Qiagen and WaferGen will promote each other's products in Japan. In particular, the companies will co-market WaferGen's SmartChip Real-Time PCR system and Qiagen's PCR arrays and next-generation sequencing platform, the latter of which is currently in an "advanced stage of development," the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.